康诺亚CM326注射液启动II期临床 适应症为中 - 极重度慢性阻塞性肺疾病

新浪财经
Oct 14

药物临床试验登记与信息公示平台数据显示,康诺亚生物医药科技(成都)有限公司的评价CM326重组人源化单克隆抗体在中 - 极重度慢性阻塞性肺疾病(COPD)参与者中的有效性和安全性的随机、双盲、安慰剂对照的临床研究已启动。临床试验登记号为CTR20253947,首次公示信息日期为2025年10月14日。该药物剂型为注射液,试验药用法用量分别为220mg Q4W皮下注射和440mg Q4W皮下注射,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10